A new partnership between Aetion and Cegedim Health Data looks to integrate real-world data compiled from European sources into clinical trial technology, Outsourcing Pharma reports.
The collaboration involves Cegedim’s The Health Improvement Network (THIN) database and the Aetion Evidence Platform.
“Over the last few months, COVID-19 has changed the drug development landscape, as leading biopharma companies, regulators, and health technology assessment bodies alike look to real world data to urgently answer questions on treatment utilization, safety and effectiveness,” Aetion CEO Carolyn Magill said. “Through this partnership with Cegedim, our aim is to help global biopharma companies quickly generate decision-grade real-world evidence by expanding our data sources and capabilities in the EU.”
To read the full report by Outsourcing Pharma, click here.